0.5 mg of semaglutide Prescribing Obesema(semaglutide) 0.5mg Injection (1 Multi-dose
Description
Who Might Benefit Most From Split Dosing
In SUSTAIN 6, subjects with T2D at high CV risk treated with semaglutide had a 26% lower risk of the primary composite outcome of first MACE (death from CV causes, nonfatal MI, or nonfatal stroke) vs those receiving placebo over 2 years (p = 0.02 for superiority [post hoc]) [12]
Prioritize third-party testing and clear labels
STEP 7 (NCT04251156) is planned to investigate the efficacy and safety of semaglutide also in the Chinese population
Youre really wasting your money.
Our success is built on relationships, trust, and seeing you thrive
